Sec Form 3 Filing - Jovan-Embiricos Morana @ TCR2 THERAPEUTICS INC. - 2019-02-13

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Jovan-Embiricos Morana 2. Issuer Name and Ticker or Trading Symbol TCR2 THERAPEUTICS INC. [ TCRR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET 3. Date of Earliest Transaction (MM/DD/YY) 02/13/2019 (Street) CAMBRIDGE, MA02142 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 1,614,515 I By Fund ( 2 ) Series B Preferred Stock ( 3 ) ( 3 ) ( 3 ) Common Stock 193,742 I By Fund ( 4 ) Series B Preferred Stock ( 3 ) ( 3 ) ( 3 ) Common Stock 410,168 I By Fund ( 5 ) Series B Preferred Stock ( 3 ) ( 3 ) ( 3 ) Common Stock 282,540 I By Fund ( 6 ) Series B Preferred Stock ( 3 ) ( 3 ) ( 3 ) Common Stock 403,629 I By Fund ( 7 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Jovan-Embiricos Morana C/O TCR2 THERAPEUTICS INC. 100 BINNEY STREET CAMBRIDGE, MA02142 X X Globeways Holdings Ltd C/O LJ PARTNERSHIP, 8, RUE SAINT-LEGER, GENEVA, V8CH-1205 X F2 Capital I 2015 Ltd C/O LJ PARTNERSHIP, 8, RUE SAINT-LEGER, GENEVA, V8CH-1205 X F2 Bioscience II 2017 Ltd C/O LJ PARTNERSHIP, 8, RUE SAINT-LEGER, GENEVA, V8CH-1205 X F2 Captial I 2017 Ltd C/O LJ PARTNERSHIP, 8, RUE SAINT-LEGER, GENEVA, V8CH-1205 X F2 MG Ltd C/O LJ PARTNERSHIP, 8, RUE SAINT-LEGER, GENEVA, V8CH-1205 X F2 - TPO Investments LLC C/O LJ PARTNERSHIP, 8, RUE SAINT-LEGER, GENEVA, V8CH-1205 X Signatures /s/ Morana Jovan-Embiricos 02/13/2019 Signature of Reporting Person Date /s/ Rachel Hingham and Ivan Bedford for Globeways Holdings Limited 02/13/2019 Signature of Reporting Person Date /s/ Rachel Hingham and Ivan Bedford for F2 Capital I 2015 Limited 02/13/2019 Signature of Reporting Person Date /s/ Rachel Hingham and Ivan Bedford for F2 Bioscience II 2017 Limited 02/13/2019 Signature of Reporting Person Date /s/ Rachel Hingham and Ivan Bedford for F2 Capital I 2017 Limited 02/13/2019 Signature of Reporting Person Date /s/ Rachel Hingham and Ivan Bedford for F2 MG Limited 02/13/2019 Signature of Reporting Person Date /s/ Rachel Hingham and Ivan Bedford for F2-TPO Investments, LLC 02/13/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Each share of Series A Preferred Stock is convertible into shares of the Issuer's common stock, par value $0.0001 ("Common Stock") on a 6.1938:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Preferred Stock has no expiration date. ( 2 )The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited. LJ Skye Trustees Ltd. has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. ( 3 )Each share of Series B Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.1938:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Preferred Stock has no expiration date. ( 4 )The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited. LJ Skye Trustees Ltd. has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. ( 5 )The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited. LJ Skye Trustees Ltd. has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. ( 6 )The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited. LJ Skye Trustees Ltd. has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. ( 7 )The reported securities are owned directly F2-TPO Investments, LLC. Globeways Holdings Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited. LJ Skye Trustees Ltd. has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.